NZ520547A - A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3 - Google Patents

A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3

Info

Publication number
NZ520547A
NZ520547A NZ520547A NZ52054701A NZ520547A NZ 520547 A NZ520547 A NZ 520547A NZ 520547 A NZ520547 A NZ 520547A NZ 52054701 A NZ52054701 A NZ 52054701A NZ 520547 A NZ520547 A NZ 520547A
Authority
NZ
New Zealand
Prior art keywords
cdr2
cdr3
amino acid
tyr
binding molecule
Prior art date
Application number
NZ520547A
Other languages
English (en)
Inventor
Hansjoerg Adam
Lothar Farber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ520547A publication Critical patent/NZ520547A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ520547A 2000-03-30 2001-03-28 A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3 NZ520547A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (1)

Publication Number Publication Date
NZ520547A true NZ520547A (en) 2005-04-29

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ520547A NZ520547A (en) 2000-03-30 2001-03-28 A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3

Country Status (18)

Country Link
US (2) US20050226872A1 (https=)
EP (1) EP1268553A1 (https=)
JP (1) JP2003528890A (https=)
KR (2) KR20080079702A (https=)
CN (1) CN1416432A (https=)
AU (2) AU4651601A (https=)
BR (1) BR0109549A (https=)
CA (1) CA2401249A1 (https=)
GB (1) GB0007911D0 (https=)
HU (1) HUP0301846A3 (https=)
IL (1) IL151089A0 (https=)
NO (1) NO20024579L (https=)
NZ (1) NZ520547A (https=)
PL (1) PL357014A1 (https=)
RU (1) RU2286797C2 (https=)
SK (1) SK13892002A3 (https=)
WO (1) WO2001072845A1 (https=)
ZA (1) ZA200207736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443405A1 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) * 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Also Published As

Publication number Publication date
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
KR20020084107A (ko) 2002-11-04
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
PL357014A1 (en) 2004-07-12
ZA200207736B (en) 2003-05-08
NO20024579L (no) 2002-11-11
SK13892002A3 (sk) 2003-05-02
IL151089A0 (en) 2003-04-10
CN1416432A (zh) 2003-05-07
US20050226872A1 (en) 2005-10-13
RU2002127800A (ru) 2004-03-27
US20090041775A1 (en) 2009-02-12
KR20080079702A (ko) 2008-09-01
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
RU2286797C2 (ru) 2006-11-10
WO2001072845A1 (en) 2001-10-04
NO20024579D0 (no) 2002-09-24
HUP0301846A3 (en) 2010-07-28
EP1268553A1 (en) 2003-01-02
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP2024174883A (ja) 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
AU2008212004B2 (en) Method for the treatment of multiple sclerosis
KR20170062505A (ko) Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
CN101657215A (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
KR20210046716A (ko) 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US20230043949A1 (en) Methods for the treatment of chronic pouchitis
JP2019508448A (ja) 移植片対宿主病予防の方法
JP2003528890A5 (https=)
CN117298268A (zh) 治疗或预防移植物抗宿主疾病的方法
US20240182581A1 (en) Methods for the treatment of chronic pouchitis
TW202028248A (zh) 使用抗ｃｄ１２３免疫結合物之治療方法
EP4547271A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
US20020110558A1 (en) Use of CD25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
RU2318537C2 (ru) Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
TW202613167A (zh) 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法
WO2026094824A1 (ja) Ｐａｄ阻害剤の自己免疫性関節炎の治療または予防のための使用
CN121568960A (zh) 治疗骨癌的方法
BR112018016226B1 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal, kit para detectar um epítopo de lam, método in vitro para diagnosticar uma infecção de tuberculose ativa em um indivíduo e método in vitro de pré-concentração de lam a partir de uma amostra biológica

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)